{"nctId":"NCT00330759","briefTitle":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.","startDateStruct":{"date":"2006-06-01","type":"ACTUAL"},"conditions":["Bone Metastases"],"count":1779,"armGroups":[{"label":"zoledronic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zoledronic Acid"]},{"label":"denosumab","type":"EXPERIMENTAL","interventionNames":["Biological: Denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":[]},{"name":"Zoledronic Acid","otherNames":["Zometa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma\n* Radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ECOG performance status 0, 1, or 2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Diagnosis of breast or prostate cancer\n* Current or prior intravenous bisphosphonate administration\n* Current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months\n* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to the First On-Study Skeletal-Related Event (Non-Inferiority)","description":"Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"496.0","spread":null},{"groupId":"OG001","value":"625.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First On-Study Skeletal-Related Event (Superiority)","description":"Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"496.0","spread":null},{"groupId":"OG001","value":"625.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to the First-and-Subsequent On-Study Skeletal-Related Event","description":"Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE.\n\nThis outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"436","spread":null},{"groupId":"OG001","value":"392","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":581,"n":878},"commonTop":["Nausea","Anaemia","Fatigue","Constipation","Dyspnoea"]}}}